Domingo José L, Gómez Mercedes
Laboratory of Toxicology and Environmental Health, School of Medicine, IISPV, Universitat Rovira i Virgili, Sant Llorenç 21, 43201, Reus, Catalonia, Spain.
Laboratory of Toxicology and Environmental Health, School of Medicine, IISPV, Universitat Rovira i Virgili, Sant Llorenç 21, 43201, Reus, Catalonia, Spain.
Food Chem Toxicol. 2016 Sep;95:137-41. doi: 10.1016/j.fct.2016.07.005. Epub 2016 Jul 11.
In the second part of the 1980s, and in the 1990s, a number of investigators demonstrated -mainly in streptozotocin-induced (STZ) diabetic rats-that the vanadate and vanadyl forms of vanadium possessed a number of insulin-like effects in various cells. It was hypothesized that oral vanadium could be an alternative treatment to parenteral insulin in the therapy of diabetes mellitus. However, the long-term and/or chronic administration of vanadium compounds should also mean tissue vanadium accumulation and risks of toxicity. The purpose of this review was to revise the current-state-of-the-art on the use of vanadium in the treatment of human diabetes. It has been conducted more than three decades after the first report on the beneficial insulin-mimetic effects of oral vanadium administration in STZ-diabetic rats. Although the antidiabetic effects of vanadium in STZ-diabetic rodents are well supported, in the few studies on human patients with positive results, that are available in the literature, vanadium compounds were administered during very short periods. We conclude that vanadium administration for the treatment of human diabetes is misplaced.
在20世纪80年代后期以及90年代，许多研究人员主要在链脲佐菌素诱导的（STZ）糖尿病大鼠中证明，钒的钒酸盐和氧钒形式在各种细胞中具有多种胰岛素样作用。有人推测，口服钒可能是糖尿病治疗中替代胃肠外胰岛素的一种治疗方法。然而，长期和/或慢性施用钒化合物也意味着组织钒蓄积和毒性风险。这篇综述的目的是修订钒在治疗人类糖尿病方面的最新技术水平。这是在首次报道口服钒对STZ糖尿病大鼠有益的胰岛素模拟作用三十多年后进行的。尽管钒对STZ糖尿病啮齿动物的抗糖尿病作用得到了充分支持，但在文献中可获得的关于人类患者的少数阳性研究中，钒化合物的给药时间非常短。我们得出结论，施用钒来治疗人类糖尿病是不合理的。
